FINWIRES · TerminalLIVE
FINWIRES

Changchun High-Tech Subsidiary Secures Chinese Regulatory Nod for Phenylketonuria Drug Clinical Trials

By

Changchun High-Tech Industry's (SHE:000661) subsidiary, Changchun GeneScience Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of GenSci144 tablets, according to a Shenzhen bourse filing on Wednesday.

The drug will be tested as a treatment for phenylketonuria, a genetic disorder caused by defects in the phenylalanine hydroxylase gene, leading to hyperphenylalaninemia.

The Chinese drug manufacturer's shares dropped 2% during the afternoon trade.

Related Articles

Asia

Haisco Pharma Gets Nod to Trial HSK44459 Cream

Haisco Pharmaceutical (SHE:002653) obtained approval from China's National Medical Products Administration for the clinical trials of the HSK44459 cream, according to a Wednesday filing on the Shenzhen bourse.The cream will be tested as a treatment for psoriasis and atopic dermatitis.

$SHE:002653
Asia

Star Sports Medicine Invests 190 Million Yuan in Wealth Products; Shares Up 3%

Star Sports Medicine (HKG:1609) subscribed to two wealth management products with a combined principal amount of 190 million yuan, according to a Tuesday Hong Kong bourse filing.Shares of the medical device company were up nearly 3% in Wednesday afternoon trade.The company subscribed to an 80 million yuan wealth management product issued by Agricultural Bank of China (HKG:1288, SHA:601288) on May 26 and a 110 million yuan product issued by Bank of Beijing on May 11, using its own funds.The company said the subscriptions were part of its routine treasury management of idle funds and followed the maturity of earlier wealth management and structured deposit investments this month.

$HKG:1288$HKG:1609$SHA:601288
Asia

Tinci Materials Tech to Build Lithium Iron Phosphate Plant for 2.10 Billion Yuan

Guangzhou Tinci Materials Technology (SHE:002709), through subsidiary Tinci Materials (Taizhou), will construct a high-pressure lithium iron phosphate plant for up to 2.10 billion yuan, according to a Shenzhen bourse filing on Wednesday.The plant will annually produce 160,000 tons of lithium iron phosphate.The Chinese new energy material manufacturer's shares rose 2% during the afternoon trade.

$SHE:002709